These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18573898)

  • 1. Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.
    Murray HW
    Infect Immun; 2008 Sep; 76(9):4088-91. PubMed ID: 18573898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.
    Murray HW; Zhang Y; Zhang Y; Raman VS; Reed SG; Ma X
    Infect Immun; 2013 Jul; 81(7):2318-26. PubMed ID: 23589575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
    Rostan O; Gangneux JP; Piquet-Pellorce C; Manuel C; McKenzie AN; Guiguen C; Samson M; Robert-Gangneux F
    mBio; 2013 Sep; 4(5):e00383-13. PubMed ID: 24045639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection.
    Murray HW; Hariprashad J; McDermott DF; Stoeckle MY
    Infect Immun; 1996 Jan; 64(1):161-6. PubMed ID: 8557335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.
    Murray HW; Luster AD; Zheng H; Ma X
    Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
    Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
    J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.
    Murray HW; Tsai CW; Liu J; Ma X
    Infect Immun; 2006 Jul; 74(7):4370-4. PubMed ID: 16790814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis.
    Murray HW
    Am J Trop Med Hyg; 2020 Nov; 103(5):1938-1941. PubMed ID: 32815498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model.
    Murray HW; Hariprashad J; Coffman RL
    J Exp Med; 1997 Mar; 185(5):867-74. PubMed ID: 9120392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
    Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
    Murray HW; Lu CM; Mauze S; Freeman S; Moreira AL; Kaplan G; Coffman RL
    Infect Immun; 2002 Nov; 70(11):6284-93. PubMed ID: 12379707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral Leishmania donovani infection in interleukin-13-/- mice.
    Murray HW; Tsai CW; Liu J; Ma X
    Infect Immun; 2006 Apr; 74(4):2487-90. PubMed ID: 16552085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.
    Murray HW; Xiang Z; Ma X
    Am J Trop Med Hyg; 2006 Jun; 74(6):1013-5. PubMed ID: 16760512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-γ-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver.
    Murray HW; Mitchell-Flack M; Taylor GA; Ma X
    Exp Parasitol; 2015 Oct; 157():103-9. PubMed ID: 26208780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
    J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.
    Murray HW; Mitchell-Flack M; Zheng H; Ma X
    Infect Immun; 2015 Feb; 83(2):702-12. PubMed ID: 25452549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA 155 Contributes to Host Immunity against Leishmania donovani but Is Not Essential for Resolution of Infection.
    Varikuti S; Natarajan G; Volpedo G; Singh B; Hamza O; Messick GV; Guerau-de-Arellano M; Papenfuss TL; Oghumu S; Satoskar AR
    Infect Immun; 2019 Aug; 87(8):. PubMed ID: 31182615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4Rα-responsive macrophages and neutrophils.
    McFarlane E; Carter KC; McKenzie AN; Kaye PM; Brombacher F; Alexander J
    J Infect Dis; 2011 Jul; 204(1):36-43. PubMed ID: 21628656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection.
    Satoskar A; Bluethmann H; Alexander J
    Infect Immun; 1995 Dec; 63(12):4894-9. PubMed ID: 7591152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
    Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
    Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.